StemCell Therapy

Here is the text of the questions submitted Feb. 12 by the California Stem Cell Report to the Institute of Medicine concerning its attempts to secure comments on the operation of the $3 billion California stem cell agency along with the IOM response.

The response from Christine Stencel, a spokeswoman for the IOM, follows these questions from the California Stem Cell Report.

"I will be writing a piece on Wednesday dealing with the online surveys that IOM has posted. For that piece, please tell me very, very  specifically what the IOM is doing to generate responses. For example, is the IOM buying ads in newspapers or online, asking the public to fill out the forms? Is it hiring a polling firm to call households for responses?  Also please tell me exactly what is being done to generate responses on all the other surveys that have been posted.

"Additionally, please tell me how many responses that the IOM has received so far in each category on the survey forms for CIRM grantees, industry partners and leadership. Thank you."

The IOM response on Feb. 15:

"The IOM has been obtaining and compiling lists of organizations and people to circulate the questionnaires as widely as possible among target groups. For example, IOM has sent a notice to some 300 stakeholder groups encouraging participation. We do not have the resources to hire a polling firm or place ads.

"The purpose of these questionnaires is to extend the committee's information gathering beyond in-person meetings and the standard listing of an email address or phone number for the study on the project website. Not all people who might have useful experiences or perspectives on CIRM may be able to attend the in-person meetings and not all may visit the project website and find the study contact information. This is a proactive effort to reach more people.

"Anyone who knows of individuals or organizations with information on CIRM that would be useful for the committee's knowledge can share the links to the questionnaires with them. This will help spread the word and get the committee insights they need.

"I don't have information on the number of responses so far. Ultimately, as noted at the top of each survey, the responses will be aggregated and de-identified and placed in the public access file in addition to being shared with the committee.

"I trust this will be useful for your readers."

The California Stem Cell Report then asked the following questions on Feb. 15.

"Thank you for your response. A few follow-up questions:
Regarding the 300 stakeholder groups, how are those defined? Please give me a few examples.

"Based on your response, is it correct to say that the IOM is not sending out questionnaires directly to all CIRM grant applicants, including those who were rejected?

"Is it correct to say that no special effort -- other than that described in your response -- is being made to seek responses from stem cell businesses?

"The failure to provide numbers on the responses so far would indicate that the numbers are so small that the IOM is choosing not to disclose them. If that is not the case, please email me the numbers. Thank you."

The IOM had not responded to the follow-up questions as of this writing on Feb. 21.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

17-02-2012 10:13 The Louis J. Fox Center for Vision Restoration received several major donations from the Western Medical Eye Bank Foundation. These donations are used to further the research on stem cell therapy for corneal scarring. Watch Mr. Wisnoski and Dr. Funderburgh discuss why this research is important.

More here:
Stem cell therapy for corneal scarring: the impact of donations - Video

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI.OB - News), a developer of innovative stem cell technologies for neurodegenerative disorders, announced that NurOwn™, its autologous stem cell therapy for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's Disease, was profiled yesterday on CNBC. In the Feature Story about the impact of Iran's nuclear threat, Israeli business and scientific leaders were interviewed about Israel's thriving economy and cutting edge technologies. Among those leaders that met with CNBC were Brainstorm’s President Mr. Chaim Lebovits and Prof. Dimitrios Karussis, Principal Investigator of Brainstorm's Phase I/II clinical trial currently underway at the Hadassah Medical Center in Jerusalem.

Brainstorm recently announced positive initial results from the clinical trial, resulting in approval from Hadassah's Helsinki committee to proceed with the trial. Accordingly, additional patients have been enrolled in the study, and Brainstorm will announce additional results in the coming months.

To see the video online, follow the link at: http://video.cnbc.com/gallery/?video=3000074883

To read the Feature Story online, follow the link at: http://www.cnbc.com/id/46484576

Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. The Company does not undertake any obligation to update forward-looking statements made by us.

Link:
BrainStorm Featured on CNBC

Global leader in animal stem cell technology is poised for significant expansion through new partnership with top U.S. companion animal health distribution company.

Las Vegas, Nevada (PRWEB) February 22, 2012

MediVet-America, the global leader in veterinary stem cell technology and regenerative medicine, has entered into a distribution partnership with Butler Schein Animal Health, a division of Henry Schein, the leading companion animal health distribution company in the U.S., to sell and distribute stem cell kits and equipment to veterinarians serving the nation’s fast-growing $50 billion pet industry.

The announcement was made today at the Western Veterinary Conference in Las Vegas by Jeremy Delk, CEO of MediVet-America.

The two companies will partner to sell and distribute MediVet-America’s advanced stem cell technology to more than 26,000 veterinary clinics nationwide. Adult animal stem cell technology uses the body’s own regenerative healing power to help treat dogs, cats, horses and other animals suffering from painful arthritis, hip dysplasia and tendon, ligament and cartilage injuries and other ailments.

The Adipose-Derived Stem Cell Procedure Kit and state of the art equipment, co-developed with Medical Australia, enable veterinarians to remove a small sample of fat, separate the stem cells, then activate and inject them into affected areas.

“We are pleased to be teaming up with Butler Schein, the largest companion animal health distribution company in the nation,” said Delk. “Their strong track record in sales and distribution will further fuel our rapid growth and bring this breakthrough technology to more leading veterinary practices across the country.”

To introduce the distribution partnership, Delk said MediVet-America has developed an exclusive program of product and service offers that will be made available only to Butler Schein customers.

Veterinary practitioners in more than 200 markets throughout 42 states now perform the drug-free procedure entirely in their own clinics more quickly, effectively and economically than earlier generation animal stem cell therapy. MediVet-America’s new treatment, developed in Australia, is available in 26 countries worldwide.

“This exciting partnership will allow even more of our colleagues unparalleled access to MediVet-America’s superior technology, providing the most affordable and efficacious stem cell therapy in the industry,” said Mike Hutchinson, D.V.M., the world’s leading animal stem cell practitioner. Dr. Hutchinson, who has spoken around the world about stem cell therapy, most recently in Tokyo, has performed more than 300 procedures over the last 18 months in his practice near Pittsburgh, PA.

Partnering with the leading animal health manufacturers in the world, Butler Schein maintains an order-fill ratio greater than 98 percent, and is positioned to bring the broadest selection of veterinary products and strategic business solutions to veterinarians, including:

    A comprehensive product offering for companion animal, equine and large animal practices including biologicals, diagnostics, nutritionals, parasiticides and pharmaceuticals

    Technology hardware and software solutions     Capital equipment, supply products and repair services     Practice design and remodeling, client marketing and financial solutions

Stem cells are basic biological cells with the ability to differentiate into specialized tissue cells and regenerate new cells to replace or repair damaged tissue. The stem cells used in veterinary medicine are not embryonic, which have attracted controversy over the years, but are taken from adipose (fat) tissue of the adult animal.

Americans spent an estimated $50.8 billion in 2011 on their companion animals, according to the American Pet Products Association, up from $28.5 billion in 2001. MediVet-America’s stem cell treatment costs about $1,800 for small animals, $2,400 for horses. Stem cells also can be frozen and banked for future use through MediVet Lab Services.

MEDIVET-AMERICA

A research and development company and global leader in veterinary stem cell technology, MediVet-America provides innovative cell applications for the therapeutic care of animals. Headquartered in Nicholasville, Kentucky, MediVet-America develops advanced cellular designed kits and services for the treatment of arthritis and degenerative joint disease. The company also offers MediVet Lab Services in multiple locations around the world that provides technical support for in-house stem cell vets, as well as regional and national Adipose stem cell processing and cryo banking services for pets at a young age or for a maintenance program, autologous conditioned serum processing, and cell counting for in-house stem cell procedures. http://www.MediVet-America.com

BUTLER SCHEIN ANIMAL HEALTH

Butler Schein Animal Health is the leading U.S. companion animal health distribution company. Headquartered in Dublin, Ohio, the company operates through 18 distribution centers and 12 telecenters. Approximately 900 Butler Schein Animal Health team members, including 300 field sales representatives and 200 telesales and customer support representatives, serve animal health customers in all 50 states. http://www.ButlerShein.com

###

Dick Roberts
Roberts Communications
(412) 535-5000
Email Information

More here:
MediVet-America Partners With Butler Schein Animal Health to Distribute World's Leading Animal Stem Cell Technology to ...

15-02-2012 18:52 Jake is one of the first dogs in the area to receive same day stem cell therapy. The new treatment gives animals better treatment in a shorter timeframe. Jake suffers from arthritis and this procedure will help ease the pain.

Visit link:
Stem cell therapy makes dog happy again - Video

AUSTIN, Texas, Feb. 21, 2012 /PRNewswire/ -- Celling Biosciences announces a sponsorship of the 7th Annual Stem Cell Summit being held on February 21st at Bridgewaters New York in New York City. The Stem Cell Summit is consistently the premiere venue for the world's leaders in regenerative medicine to network and promote next generation technologies and cell therapies.

The meeting will feature more than 30 thought leaders in stem cell therapy including Dr. Kenneth Pettine of the Orthopedic Stem Cell Institute in Loveland, Colorado.  Dr. Pettine has teamed up with Celling Biosciences' SpineSmith Division to present "Adult Stem Cell Therapy for Orthopedic and Spine Conditions Resulting from Injury or Aging."  Dr. Pettine has become an innovator in the regenerative cell therapy market and believes "regenerative therapies will become the next standard of care in treating many orthopedic conditions." 

Following the Stem Cell Summit, Dr. Pettine will be presenting a discussion on regenerative therapies to the trainers and medical staff attending this year's NFL combine.  The NFL has recently gained attention from Peyton Manning going oversees to receive a cell therapy treatment for his cervical spine condition.  Dr. Pettine envisions a day when these professional athletes stop going to foreign countries to receive medical treatment.

The Orthopedic Stem Cell Institute provides state-of-the-art regenerative cell therapy using Celling Biosciences' ART 21 system. The ART 21 system processes bone marrow from the patient at the point of care to consistently produce a concentrate of regenerative cells with high yields of mononuclear stem cells in less than 15 minutes.  Celling Biosciences provides the cell separation systems along with the biomaterials and devices necessary to recreate the environment to promote healing. 

Kevin Dunworth, founder of Celling Biosciences, believes regenerative cell therapy has more to do with creating the optimal environment then just providing cells.  "We believe autologous cell therapy is a viable solution but physicians need to understand that these cells require the necessary substrate for delivery and the proper techniques for retrieval.  Our focus has been on providing not only cell separation technologies, medical devices and biomaterials but also the registered nurses to deliver the service so physicians can have the most consistent, reliable and predictable regenerative cell therapy for their patients."

Contact:
Tracy Gladden
Communications Manager
Tgladden@spinesmithusa.com
512-637-2050

About Celling Biosciences
Celling Biosciences, works closely with surgeons, scientists and engineers to research and develop innovative technologies in the field of regenerative medicine. http://www.cellingbiosciences.com and http://www.spinesmithusa.com

Continue reading here:
Celling Biosciences Sponsors 7th Annual Stem Cell Summit

19-12-2011 14:50 Katie Sharify, 23, of Pleasanton, receives stem cells for a spinal cord injury.

View original post here:
Stem cell therapy at VMC - Video

20-12-2011 09:01 If you would like more information please call us Toll Free at 877-578-7908. Or visit our website at http://www.usastemcells.com Or click here to have a Free Phone Constultation with Dr. Matthew Burks usastemcells.com Real patient testimonials for USA Stem Cells. Adult stem cell therapy for COPD, Emphysema, and Pulmonary fibrosis.

Follow this link:
Adult Stem Cell Treatments for COPD -Real patient results, USA Stem Cells- Donald W. Testimonial - Video

15-02-2012 13:27 Hear from the family of a teenager who no longer suffers from sickle cell disease after receiving a stem cell transplant in a clinical trial NSCF funds. NSCF funds clinical trials to: • Induce drug-free tolerance for transplanted kidneys • Effectively cure inherited red blood cell disorders like sickle cell disease (SCD) and thalassemia •Permanently correct fatal childhood enzyme deficiencies For more information visit nationalstemcellfoundation.org.

Read this article:
The Igwe Family - Adult Stem Cell Therapy for Sickle Cell Disease - Video

The mainstream media waxed enthusiastic last month when a California hESC clinical trial reported positive results dealing with blindness.

The report was first published account of a human trial of embryonic stem cell based therapy and involved Advanced Cell Technology, which is headquartered in Santa Monica, Ca. Despite a glowing reception of the trial's results, the firm is years away from being able to market the therapy at a profit – if it ever can do so.

The firm's chief scientific officer, Robert Lanza, moved quickly, however, to capture some monetary gain from the news, which was announced in a press release Jan. 23 by ACT.

On Jan. 23 and 24, Lanza sold 7.7 million shares in ACT for $1.5 million, according to SEC documents. He sold the stock at 18 and 19 cents a share. That compares to an ACT price of about 8 cents at the end of 2011. Lanza still holds 26 million shares in the firm. The acquisition price of the stocks is unknown.

There is nothing to suggest anything untoward about Lanza's sale. But it is a reminder that creating a successful stem cell therapy is about making money. Without a profit, there will be no therapy, as Geron reminded everyone last November when it dropped its longstanding hESC trial.

The California Stem Cell Report has asked Lanza if he has any comments about the sale of the stock. We will carry his remarks verbatim when we receive them.

The Seeking Alpha web site appears to have been the first to report the sale. Here is their complete item.

"Advanced Cell Technology, Inc. (ACTC.OB): ACTC is a development-stage biotech focused on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. On Wednesday, Chief Science Officer Robert Lanza filed SEC Form 4 indicating that he sold 7.7 million shares for $1.5 million, ending with 26.0 million shares after that sale. ACTC shares have rallied strongly since the beginning of the year, up from 8.2 cents at the end of last year to currently in 14-15c range after rising above 20c just earlier this week."

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

The California stem cell agency this week performed its semi-annual public disclosure of its contracts with outside firms, the second largest item in its operational budget of $18.5 million.

The contracts are scheduled to run about $3.3 million this fiscal year, according to the budget approved last May. That figure is up about 18 percent from the previous year.

According to the contract information posted this week, the two largest contracting expenditures this year are for information technology work, including the ongoing struggles with the grants management system – $1.3 million – and legal help – $887,282. The figures were compiled by the California Stem Cell Report. CIRM did not provide totals.

Outside contracts are second to the cost of salaries and benefits at the agency. One reason for the size of the contracting expense is the small size of the CIRM staff, which is now about 50.

The contracting information will be presented to the CIRM directors' Governance Subcommittee next Friday. The committee is being asked to approve an increase in the contract with Kutir Corp., from $250,000 to $470,000. By the end of 2011, CIRM had already paid out $219,680 to Kutir. The firm provides software development services.

Infonetica, which provides technology advice, would also see an increase from $236,060 to $300,000, under the staff proposal.

A staff memo to the board said,

"(Kutir's) services are key as CIRM continues to progress in automating its grants management systems to meet the requirements of both new RFAs as well as ongoing reporting obligations.""

The public can participate in the Governance meeting at locations in San Francisco, Sacramento, Irvine, Los Angeles, South San Francisco and La Jolla. Specific addresses can be found on the agenda.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

The California stem cell agency today said the seven-year-old "audacious vision" of voters when they created the $3 billion research effort "is still possible."

The comment was made in an item on the agency's blog by Amy Adams, the agency's communications manager.

Her entry point was an opinion piece in The Sacramento Bee on Sunday exploring some of the ins and outs of the agency. Among other things, CIRM President Alan Trounson was quoted by writer David Lesher as "optimistically" predicting successful California stem cell treatments in five years.

Adams wrote,

"Lesher makes clear that there are many challenges ahead in bringing new therapies to patients: he said of the voters who created CIRM, 'It was pretty audacious of them in 2004 to try to create another economic driver like Silicon Valley and save lives at the same time.'

"And while the vote was audacious, we agree with his conclusion that despite risks and challenges that vision is still possible." 

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

The California public is being given a chance to weigh in with anonymous comments about what they think of the performance of the $3 billion California stem cell agency.

Their opinions are being sought by a blue-ribbon, Institute of Medicine panel. The IOM is being paid $700,000 by the agency to examine its operations.

The questions include the importance of stem cell research and CIRM's role, its openness and transparency, an assessment of its grant programs and how it should share information with the public, suggestions for improvements and more.

The online form was posted recently on the IOM web site and can be found here. The deadline for submissions is March 19.

The IOM also has survey forms for academic and non-profit CIRM grant recipients, CIRM grant recipients that are businesses(which the IOM calls "industry partners") and "leadership of CIRM-funded institutions." The deadline for those is March 19 as well.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

The California stem cell agency this week performed its semi-annual public disclosure of its contracts with outside firms, the second largest item in its operational budget of $18.5 million.

The contracts are scheduled to run about $3.3 million this fiscal year, according to the budget approved last May. That figure is up about 18 percent from the previous year.

According to the contract information posted this week, the two largest contracting expenditures this year are for information technology work, including the ongoing struggles with the grants management system – $1.3 million – and legal help – $887,282. The figures were compiled by the California Stem Cell Report. CIRM did not provide totals.

Outside contracts are second to the cost of salaries and benefits at the agency. One reason for the size of the contracting expense is the small size of the CIRM staff, which is now about 50.

The contracting information will be presented to the CIRM directors' Governance Subcommittee next Friday. The committee is being asked to approve an increase in the contract with Kutir Corp., from $250,000 to $470,000. By the end of 2011, CIRM had already paid out $219,680 to Kutir. The firm provides software development services.

Infonetica, which provides technology advice, would also see an increase from $236,060 to $300,000, under the staff proposal.

A staff memo to the board said,

"(Kutir's) services are key as CIRM continues to progress in automating its grants management systems to meet the requirements of both new RFAs as well as ongoing reporting obligations.""

The public can participate in the Governance meeting at locations in San Francisco, Sacramento, Irvine, Los Angeles, South San Francisco and La Jolla. Specific addresses can be found on the agenda.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

The mainstream media waxed enthusiastic last month when a California hESC clinical trial reported positive results dealing with blindness.

The report was first published account of a human trial of embryonic stem cell based therapy and involved Advanced Cell Technology, which is headquartered in Santa Monica, Ca. Despite a glowing reception of the trial's results, the firm is years away from being able to market the therapy at a profit – if it ever can do so.

The firm's chief scientific officer, Robert Lanza, moved quickly, however, to capture some monetary gain from the news, which was announced in a press release Jan. 23 by ACT.

On Jan. 23 and 24, Lanza sold 7.7 million shares in ACT for $1.5 million, according to SEC documents. He sold the stock at 18 and 19 cents a share. That compares to an ACT price of about 8 cents at the end of 2011. Lanza still holds 26 million shares in the firm. The acquisition price of the stocks is unknown.

There is nothing to suggest anything untoward about Lanza's sale. But it is a reminder that creating a successful stem cell therapy is about making money. Without a profit, there will be no therapy, as Geron reminded everyone last November when it dropped its longstanding hESC trial.

The California Stem Cell Report has asked Lanza if he has any comments about the sale of the stock. We will carry his remarks verbatim when we receive them.

The Seeking Alpha web site appears to have been the first to report the sale. Here is their complete item.

"Advanced Cell Technology, Inc. (ACTC.OB): ACTC is a development-stage biotech focused on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. On Wednesday, Chief Science Officer Robert Lanza filed SEC Form 4 indicating that he sold 7.7 million shares for $1.5 million, ending with 26.0 million shares after that sale. ACTC shares have rallied strongly since the beginning of the year, up from 8.2 cents at the end of last year to currently in 14-15c range after rising above 20c just earlier this week."

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

The California stem cell agency today said the seven-year-old "audacious vision" of voters when they created the $3 billion research effort "is still possible."

The comment was made in an item on the agency's blog by Amy Adams, the agency's communications manager.

Her entry point was an opinion piece in The Sacramento Bee on Sunday exploring some of the ins and outs of the agency. Among other things, CIRM President Alan Trounson was quoted by writer David Lesher as "optimistically" predicting successful California stem cell treatments in five years.

Adams wrote,

"Lesher makes clear that there are many challenges ahead in bringing new therapies to patients: he said of the voters who created CIRM, 'It was pretty audacious of them in 2004 to try to create another economic driver like Silicon Valley and save lives at the same time.'

"And while the vote was audacious, we agree with his conclusion that despite risks and challenges that vision is still possible." 

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

The California public is being given a chance to weigh in with anonymous comments about what they think of the performance of the $3 billion California stem cell agency.

Their opinions are being sought by a blue-ribbon, Institute of Medicine panel. The IOM is being paid $700,000 by the agency to examine its operations.

The questions include the importance of stem cell research and CIRM's role, its openness and transparency, an assessment of its grant programs and how it should share information with the public, suggestions for improvements and more.

The online form was posted recently on the IOM web site and can be found here. The deadline for submissions is March 19.

The IOM also has survey forms for academic and non-profit CIRM grant recipients, CIRM grant recipients that are businesses(which the IOM calls "industry partners") and "leadership of CIRM-funded institutions." The deadline for those is March 19 as well.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

World Stem Cells, LLC Stem Cell Therapy at a state of the art clinic in beautiful Cancun. The clinic is staffed by top specialist in the field of stem cell implants and a new laboratory to support the stem cell treatments given.

(PRWEB) February 16, 2012

World Stem Cells, LLC. contract laboratory Advanced Cellular Engineering Lab (Ingenieria Celular Advanzada S.A. de C.V.) a new adult stem cell laboratory being built in Cancun, Mexico to support Stem Cell research, stem cell clinical trials and stem cell treatments. This was accomplished by private funding in conjunction with World Stem Cells, LLC worldstemcells.com a US patient management company, Medicina Biocelular Avanzada , S.E. de C.V. a Mexican patient management company and Advanced Cellular Medicine Clinic of Cancun, a Stem Cell treatment Clinic owned and operated by Dr. Sylvia M. Abblitt a well known board certified hematologist and oncologist, in Cancun.

Uniquely, Dr. Abblitt is one of a limited number of physicians licensed to perform autologous and allogeneic stem cell transplants. Dr. Abblitt has been utilizing stem cell therapies with successes for many years.

She is the president and lab director of Advanced Cellular Engineering Lab (Ingenieria Celular Advanzada S.A. de C.V.). Her extensive background includes having been the laboratory director and head of hematology for Hospital Fernando Quiroz for 11 years. As a pioneer in the stem cell transplant field, she brings a vast array of knowledge to the lab. Her memberships include the american association of blood banks (aabb), Mexican society of transfusional medicine, interamerica society of transfusional medicine, Mexican association) for studies of hematologyandicms and ICMS (international cellular medical society and all patients are monitored by ICMS an independent agency for a period of between 2-20 years on a quarterly basis. Dr. abblitt has had a 26-year clinical practice history.

The laboratory construction is complete and operations were transferred to our new facility. This facility provides Cancun, and patient around the world, a state of the art GLP laboratory to support their stem cell treatments in a beautiful, and positive environment. The lab was designed and constructed to provide one ISO7 lab, one wet lab along with a treatment area. This will allow stem cell retrieval, testing, culturing, selection, counting, analyses and sorting along with cryopreservation, without removal from the lab. This all in house capability reduces the possibility of contamination and errors. Dr. M. Abblitt will operate the Lab under cGMP/cGLP guidelines and use the state of the art facility to provide quality care to her stem cell transplant patients.

Working under the guidelines set forth by ICMS world stem cells, LLC ( http://worldstemcells.com/ ) provides stem cell treatment for ankylosing spondylitis, autism, cerebral palsy, charcot-marie-tooth disease (cmt), crohn’s diseases, copd, fuch’s disease, guillain-barre’ syndrome, hashimoto’s thryroiditis, itp, kidney diseases, macular degeneration, lupus (sle), multiple sclerosis, pad, parkinson’s disease, rheumatoid arthritis, scleroderma, stroke, ulcerative colitis

The laboratory will be engaged in private clinical trials, IRB’s and joint studies with US companies, Mexican Educational Institutes, US universities and doctors to better understand the benefits and precaution to be taken in the stem cell treatment process.

###

Charles Newcomer

727-421-4359
Email Information

Read the original:
World Stem Cells, LLC. Stem Cell Treatments In Cancun at Advanced Cellular Medicine Clinic

NEW YORK, NY--(Marketwire -02/15/12)- Stem cell stocks have performed well of late, outperforming the S&P 500 by a large margin over the last three months. Since mid-November, TickerSpy's Stem Cell Stocks index (RXSTM) has returned more than 20 percent, as favorable news from some of stem cell industry heavyweights has boosted investor optimism in the sector. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Cytori Therapeutics, Inc. (NASDAQ: CYTX - News) and Cord Blood America, Inc. (OTC.BB: CBAI.OB - News). Access to the full company reports can be found at:

http://www.paragonreport.com/CYTX

http://www.paragonreport.com/CBAI

Shares of Cytori Therapeutics have skyrocketed nearly 70 percent year-to-date. The company develops, manufactures, and sells medical products and devices to enable the practice of regenerative medicine. The Company's technology is the Celuion family of products, which processes patients' adipose-derived stem and regenerative cells (ADRCs) at the point of care.

In late January, Cytori received an Investigational Device Exemption (IDE) approval from the U.S. FDA to begin the "ATHENA" trial. ATHENA will investigate the use of the Celution System to treat a form of coronary heart disease, chronic myocardial ischemia (CMI).

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at http://www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

Cord Blood America, Inc. is a holding company that, through its subsidiaries, is engaged in the business of collecting, testing, processing and preserving umbilical cord blood, thereby allowing families to preserve cord blood at the birth of a child for potential use in stem cell therapy.

USA Today recently reported that umbilical cord blood stem cells have been successfully used to treat individuals with type 1 diabetes, highlighting the importance of storing stem cells at birth. The USA Today article says that stem cells from cord blood have been used to "reeducate" the immune system T cells of people with type 1 diabetes so their pancreas started producing insulin again - thereby reducing the amount of insulin they needed to inject.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer

Link:
Stem Cell Stocks Skyrocket in 2012 -- Cytori Therapeutics and Cord Blood America on the Upswing

A new study at Johns Hopkins University has shown that stem cells from patients' own cardiac tissue can be used to heal scarred tissue after a heart attack. This is certainly exciting news considering heart failure is still the No. 1 cause of death in men and women.

The study included 25 heart attack victims, 17 of whom got the stem cell treatment. Those patients saw a 50% reduction in cardiac scar tissue after one year, while the eight control patients saw no improvement.

The procedure involves removing a tiny portion of heart tissue through a needle, cultivating the stem cells from that tissue, and reinserting them in a second minimally invasive procedure, according to Bloomberg.

"If we can regenerate the whole heart, then the patient would be completely normal," said Eduardo Marban, director of Cedars-Sinai Heart Institute who was the study's lead author. "We haven't fulfilled that yet, but we've gotten rid of half of the injury, and that's a good start."

Business section: Investing ideas
Interested in investing in the promise that stem cell therapy holds? For a look at the investing landscape, we compiled a list of the 10 largest companies involved in stem cell therapy.

Do you think this industry will see growth from stem cell research? (Click here to access free, interactive tools to analyze these ideas.)

1. BioTime (NYSE: BTX  ) : Focuses on regenerative medicine and blood plasma volume expanders. Market cap at $291.95M. The company develops and markets research products in the field of stem cells and regenerative medicine. It develops therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases; cardiovascular and blood diseases; therapeutic applications of stem cells to treat orthopedic diseases, injuries, and cancer; and retinal cell product for use in the treatment of age-related macular degeneration.

2. Cleveland BioLabs (Nasdaq: CBLI  ) : Market cap at $111.50M. Its products include Protectan CBLB502, a radioprotectant molecule with multiple medical and defense applications for reducing injury from acute stresses, such as radiation and chemotherapy by mobilizing various natural cell protecting mechanisms, including inhibition of apoptosis, reduction of oxidative damage, and induction of factors that induce protection and regeneration of stem cells in bone marrow and the intestines, and Protectan CBLB612, a modified lipopeptide mycoplasma that acts as a stimulator and mobilizer of hematopoietic stem cells to peripheral blood, providing hematopoietic recovery during chemotherapy and during donor preparation for bone marrow transplantation.

3. Gentium: Focuses on the development and manufacture of its primary product candidate, defibrotide, an investigational drug based on a mixture of single-stranded and double-stranded DNA extracted from pig intestines. Market cap at $128.29M. The company develops defibrotide for the treatment and prevention of hepatic veno-occlusive disease (VOD), a condition that occurs when veins in the liver are blocked as a result of cancer treatments, such as chemotherapy or radiation, that are administered prior to stem cell transplantation.

4. Geron (Nasdaq: GERN  ) : Develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes. Market cap at $265.57M. The company has licensing agreement with the University Campus Suffolk to develop human embryonic stem cell-derived chondrocytes for the treatment of cartilage damage and joint disease.

5. Harvard Bioscience: Develops, manufactures, and markets apparatus and scientific instruments used in life science research in pharmaceutical and biotechnology companies, universities, and government laboratories in the United States and internationally. Market cap at $118.28M. Develops devices used by clinicians and researchers in the field of regenerative medicine, including bioreactors for growing tissue and organs outside the body, and injectors for stem cell therapy.

6. Lydall (NYSE: LDL  ) : Designs and manufactures specialty engineered products for thermal/acoustical, filtration/separation, and bio/medical applications in the United States. Market cap at $163.44M. In addition, it offers Cell-Freeze, a medical device used for cryogenic storage of peripheral blood stem cells.

8. Osiris Therapeutics (Nasdaq: OSIR  ) : Focuses on the development and marketing of therapeutic products to treat various medical conditions in the inflammatory, autoimmune, orthopedic, and cardiovascular areas. Market cap at $157.26M. A stem cell company, focuses on the development and marketing of therapeutic products to treat various medical conditions in the inflammatory, autoimmune, orthopedic, and cardiovascular areas.

7. Verastem: Market cap at $229.00M. Focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) in breast and other cancers.

Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the stocks mentioned above. Analyst ratings sourced from Zacks Investment Research.

Kapitall's Alexander Crawford does not own any of the shares mentioned above.

The rest is here:
Stem Cell Stocks: Mending Scarred Hearts